Document is current
Any future updates will be listed below
-
Authors
Thomassen, Emil Eirik Kvernberg https://orcid.org/0000-0003-2075-999X
Berg, Inger Jorid https://orcid.org/0000-0002-8605-5488
Kristianslund, Eirik Klami https://orcid.org/0000-0002-4963-3285
Tveter, Anne Therese https://orcid.org/0000-0003-1701-9835
Bakland, Gunnstein https://orcid.org/0000-0003-2613-5176
Gossec, Laure https://orcid.org/0000-0002-4528-310X
Hakim, Sarah https://orcid.org/0009-0006-3567-0313
Macfarlane, Gary John https://orcid.org/0000-0003-2322-3314
de Thurah, Annette https://orcid.org/0000-0003-0103-4328
Østerås, Nina https://orcid.org/0000-0001-8602-342X
-
Funding
Funding for this research was provided by:
Helse Sør-Øst RHF (2021062)
Norges Forskningsråd (328657)
University of Oslo
- License Information
-
More Information
Article History
Received: 29 May 2024
Accepted: 27 July 2024
First Online: 21 August 2024
Declarations
:
: GB has received lecture honoraria from Janssen Pharmaceuticals. LG has received grants from AbbVie, Biogen, Lilly, Novartis, UCB. LG has received consulting fees from AbbVie, Amgen, BMS, Celltrion, Janssen, Novartis, Pfizer, UCB. LG has received lecture honoraria from AbbVie, Amgen, BMS, Celltrion, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB. LG has received support for meetings from MSD, Novartis, Pfizer. LG has participated in advisory boards at Janssen, Pfizer, UCB. LG received medical writing support from Abbvie, Amgen, Galapagos, Janssen, Pfizer, UCB.
: The study was conducted according to the Helsinki declaration and was approved by the Regional Committees for Medical and Health Research Ethics South East Norway (ref: 229187).
